403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
US FDA Approves Astrazeneca, Daiichi's Breast Cancer Drug As First-Line Treatment
(MENAFN- Khaleej Times)
The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said on Monday.
The drug, sold under the brand name Enhertu, co-developed by Daiichi Sankyo and AstraZeneca, originally won US approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients.
Recommended For YouThe new approval allows the use of Enhertu with Roche's Perjeta to treat adults with advanced HER2-positive breast cancer confirmed by an FDA-approved test.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment